NCT04953325View on ClinicalTrials.gov

Immunogenicity and Safety of an Inactivated COVID-19 Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

July 9, 2021

Primary Completion Date

October 31, 2021

Study Completion Date

January 31, 2022

Conditions
COVID-19
Interventions
BIOLOGICAL

Inactivated COVID-19 Vaccine

600SU inactivated virus in 0·5 mL of aluminium hydroxide solution per injection

BIOLOGICAL

23-valent pneumococcal polysaccharide vaccine

25μg each of the following serotypes/each dose (0.5ml): 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F

BIOLOGICAL

Inactivated Hepatitis A Vaccine

500SU inactivated Hepatitis A virus in 1 mL of aluminium hydroxide solution per injection.

Trial Locations (1)

250014

Rushan City Center for Disease Control and Prevention, Weihai

All Listed Sponsors
lead

Sinovac Research and Development Co., Ltd.

INDUSTRY